Isogenica is pleased to welcome both Paul Clewlow and Trevor Phillips as our new Non-Executive Directors to the team.

Isogenica, a leading innovator in VHH antibodies, is proud to unveil two significant collaborations, demonstrating the company’s commitment to advancing healthcare through cutting-edge research and development.

Patients could benefit from bespoke cancer-fighting treatments with fewer side effects thanks to a new partnership between a biotech company and a UK university.